Verve won trial success with a gene-editing milestone. Why don't investors like it?
This weekend, Verve Therapeutics presented the first-ever results of an in vivo base editing therapy in humans, marking a major milestone not only for the company but also for the gene editing field as a whole. But on Monday morning, the biotech’s stock tumbled 40% over questions about the treatment’s potential to lead a market.
“The Verve data are truly a major scientific milestone that is part of a new frontier of medicine,” said John Maraganore, the former CEO of RNA therapeutics company Alnylam. “But sometimes markets don’t appreciate that as much.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.